Background: We analyzed the clinicopathological features and prognosis in patients with periocular sebaceous gland carcinoma. Methods: Retrospectively, we studied the records of 24 cases of sebaceous gland carcinoma treated in our clinic between 1999 and 2004. The reviewed data included demographic information, initial clinical and histopathological diagnosis, anatomic tumor location, details of treatment, tumor involvement of resection margin, and outcomes such as local recurrence, distant metastasis and survival. Results: Local recurrence developed in 6 cases (25%) at a median of 20 months from initial diagnosis. Only 2 patients (8.3%) died of systemic metastasis to brain and bone from primary lacrimal gland carcinoma. The local recurrence rate in the complete excision group (5.9%) was significantly lower compared with the incomplete excision with irradiation group (71.4%; Fisher’s exact test, p = 0.003). We observed a shorter duration of symptom, a higher rate of eventual exenteration and local recurrence, and a shorter time interval to local recurrence from initial management in poorly differentiated tumors compared with moderately differentiated tumors. Conclusion: It is critical to achieve a negative tumor margin in both frozen and permanent section to prevent local recurrence. Early aggressive management is required in sebaceous gland carcinoma of the lacrimal gland, as its mortality is much higher than that of eyelid origin.

Keywords:
Complete excision, Differentiation, sebaceous, Lacrimal gland, Sebaceous gland carcinoma, prognosis
1.
Roh KK, Lee JH, Youn DH: Clinical analysis of tumors of the eye and its adnexa. Korean J Ophthalmol 1988;2:27–31.
2.
Ni C, Searl SS, Kuo PK, et al: Sebaceous cell carcinomas of the ocular adnexa. Int Ophthalmol Clin 1982;22:23–61.
3.
Lee SB, Saw SM, Au Eong KG, et al: Incidence of eyelid cancers in Singapore from 1968 to 1995. Br J Ophthalmol 1999;83:595–597.
4.
Sihota R, Tandon K, Betharia SM, Arora R: Malignant eyelid tumors in an Indian population. Arch Ophthalmol 1996;114:108–109.
5.
Abdi U, Tyagi N, Maheshwari V, et al: Tumours of eyelid: a clinicopathologic study. J Indian Med Assoc 1996;94:405–409.
6.
Takamura H, Yamashita H: Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol 2005;49:349–354.
7.
Kwitko ML, Boniuk M, Zimmerman LE: Eyelid tumors with reference to lesions confused with squamous cell carcinoma. I. Incidence and errors in diagnosis. Arch Ophthalmol 1963;69:693–697.
8.
Cook BE Jr, Bartley GB: Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 1999;106:746–750.
9.
Shields JA, Demirci H, Marr BP, et al: Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology 2004;111:2151–2157.
10.
Muqit MM, Roberts F, Lee WR, Kemp E: Improved survival rates in sebaceous carcinoma of the eyelid. Eye 2004;18:49–53.
11.
Nelson BR, Hamlet KR, Gillard M, et al: Sebaceous carcinoma. J Am Acad Dermatol 1995;33:1–15.
12.
Rao NA, Hidayat AA, McLean IW, Zimmerman LE: Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol 1982;13:113–122.
13.
Burns SJ, Foss AJ, Butler TK: Outcome of periocular sebaceous gland carcinoma. Ophthal Plast Reconstr Surg 2005;21:353–355.
14.
Doxanas MT, Green WR: Sebaceous gland carcinoma: review of 40 cases. Arch Ophthalmol 1984;102:245–249.
15.
LeBoit PE, Burg G, Weedon D, Sarasin A: Pathology and Genetics of Skin Tumours, ed 1. Lyon, International Agency for Research on Cancer, 2006.
16.
Lai TF, Huilgol SC, Selva D, James CL: Eyelid sebaceous carcinoma masquerading as in situ squamous cell carcinoma. Dermatol Surg 2004;30:222–225.
17.
Zurcher M, Hintschich CR, Garner A, et al: Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol 1998;82:1049–1055.
18.
Boniuk M, Zimmerman LE: Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit. Trans Am Acad Ophthalmol Otolaryngol 1968;72:619–642.
19.
Pereira PR, Odashiro AN, Rodrigues-Reyes AA, et al: Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol 2005;32:496–501.
20.
Rodgers IR, Jakobiec FA, Gingold MP, et al: Anaplastic carcinoma of the lacrimal gland presenting with recurrent subconjunctival hemorrhages and displaying incipient sebaceous differentiation. Ophthal Plast Reconstr Surg 1991;7:229–237.
21.
Witschel H, Zimmerman LE: Malignant mixed tumor of the lacrimal gland: a clinicopathologic report of two unusual cases. Graefes Arch Clin Exp Ophthalmol 1981;216:327–337.
22.
Konrad EA, Thiel HJ: Adenocarcinoma of the lacrimal gland with sebaceous differentiation: a clinical study using light and electron microscopy. Graefes Arch Clin Exp Ophthalmol 1983;221:81–85.
23.
Harvey PA, Parsons MA, Rennie IG: Primary sebaceous carcinoma of lacrimal gland: a previously unreported primary neoplasm. Eye 1994;8:592–595.
24.
Briscoe D, Mahmood S, Jackson A, Leatherbarrow B: Primary sebaceous cell carcinoma of the lacrimal gland. Br J Ophthalmol 2001;85:623–633.
25.
Yamamoto N, Mizoe JE, Hasegawa A, et al: Primary sebaceous carcinoma of the lacrimal gland treated by carbon ion radiotherapy. Int J Clin Oncol 2003;8:386–390.
26.
Colak A, Akkurt C, Ozcan OE, Onol B: Intracranial extension of meibomian gland carcinoma. J Clin Neuroophthalmol 1991;11:39–42.
27.
Burns SJ, Foss AJ, Butler TK: Outcome of periocular sebaceous gland carcinoma. Ophthal Plast Reconstr Surg 2005;21:353–355.
28.
Folberg R, Whitaker DC, Tse DT, Nerad JA: Recurrent and residual sebaceous carcinoma after Mohs’ excision of the primary lesion. Am J Ophthalmol 1987;103:817–823.
29.
Yount AB, Bylund D, Pratt SG, Greenway HT: Mohs micrographic excision of sebaceous carcinoma of the eyelids. J Dermatol Surg Oncol 1994;20:523–529.
30.
Khan JA, Doane JF, Grove AS Jr: Sebaceous and meibomian carcinomas of the eyelid: recognition, diagnosis, and management. Ophthal Plast Reconstr Surg 1991;7:61–66.
31.
Shields JA, Demirci H, Marr BP, et al: Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol 2005;50:103–122.
32.
Pettey AA, Walsh JS: Muir-Torre syndrome: a case report and review of the literature. Cutis 2005;75:149–155.
33.
Schwartz RA, Torre DP: The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 1995;33:90–104.
34.
Conway RM, Moller A, Ballhausen W, et al: Frequency and clinical features of visceral malignancy in a consecutive case series of patients with periocular sebaceous gland carcinoma. Graefe’s Arch Clin Exp Ophthalmol 2004;242:674–678.
35.
Weinstein A, Nouri K, Bassiri-Tehrani S, et al: Muir-Torre syndrome: a case of this uncommon entity. Int J Dermatol 2006;45:311–313.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.